Introduction: Urinary and erectile functions were assessed by using self-administered validated questionnaires in patients undergoing radical prostatectomy. Materials and Methods: In a prospective observational study, a total of 253 consecutive patients diagnosed with clinically localised prostate cancer between 2008 and 2009 at the European Prostate Centre Innsbruck were included. Patient-reported outcomes were assessed before radical prostatectomy and 12 months postoperatively using the validated International Consultation on Incontinence Questionnaire (ICIQ) and the International Index of Erectile Function (IIEF). The Wilcoxon signed-rank test and Chi square statistics were used for analysis. Results: The study showed that before radical prostatectomy, urinary incontinence of various severity grades was reported in 18.8, postoperatively in 63.0% (p < 0.001) and erectile dysfunction of various degrees was reported in 39.6 at baseline compared to 80.1% 12 months postoperatively (p < 0.001). Conclusions: This study suggests that radical prostatectomy is associated with a significantly increased risk of urinary incontinence and erectile dysfunction 12 months postoperatively.

Keywords:
Erectile dysfunction, Prostatectomy, Prostatic neoplasms, Urinary incontinence
1.
Statistik Austria, 2013.
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3.
Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P: Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008;101:809-816.
4.
Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G, Frauscher F, Schennach H, Bartsch G: Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 2012;57:57-62.
5.
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H: Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-732.
6.
Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, Chevrette E, Levesque J: Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59:311-318.
7.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
8.
Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P: Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342:d1539.
9.
Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K: Screening for prostate cancer: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011;155:762-771.
10.
Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P: Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
11.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P: Screening for prostate cancer. Cochrane Database Syst Rev 2013;1:CD004720.
12.
PSA-based screening for prostate cancer. Too many adverse effects. Prescrire Int 2012;21:215-217.
13.
Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-878.
14.
Pashayan N, Duffy SW, Pharoah P, Greenberg D, Donovan J, Martin RM, Hamdy F, Neal DE: Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 2009;100:1198-1204.
15.
Pelzer AE, Colleselli D, Bektic J, Schaefer G, Ongarello S, Schwentner C, Pallwein L, Mitterberger M, Steiner E, Bartsch G, Horninger W: Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference? BJU Int 2008;102:24-27.
16.
Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, Zappa M, Tammela TL, Makinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schroder FH, de Koning HJ: Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595-605.
17.
Kyrdalen AE, Dahl AA, Hernes E, Smastuen MC, Fossa SD: A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221-232.
18.
Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL: Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435-448.
19.
Froehner M, Scholz A, Koch R, Hakenberg OW, Baretton GB, Wirth MP: Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy. Urol Int 2012;89:148-154.
20.
Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P: ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004;23:322-330.
21.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
22.
STATA Statistical Software: Stata Statistical Software: Release 11 College Station, TX, StataCorp LP, 2009.
23.
Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Stranne J, Hugosson J: The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Goteborg randomised population-based prostate cancer screening trial. Eur J Cancer 2011;47:545-553.
24.
Koehler N, Holze S, Gansera L, Rebmann U, Roth S, Scholz HJ, Fahlenkamp D, Thiel R, Braehler E: Erectile dysfunction after radical prostatectomy: the impact of nerve-sparing status and surgical approach. Int J Impot Res 2012;24:155-160.
25.
Shamliyan TA, Wyman JF, Ping R, Wilt TJ, Kane RL: Male urinary incontinence: prevalence, risk factors, and preventive interventions. Rev Urol 2009;11:145-165.
26.
Treiyer A, Anheuser P, Butow Z, Steffens J: A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy. J Urol 2011;185:1681-1685.
27.
Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ: Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172:2227-2231.
28.
Levinson AW, Ward NT, Sanda MG, Mettee LZ, Wei JT, Su LM, Litwin MS, Pavlovich CP: Comparison of validated instruments measuring sexual function in men. Urology 2010;76:380-386.
29.
Krahn MD, Bremner KE, Tomlinson G, Naglie G: Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer Prostatic Dis 2009;12:361-368.
30.
Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL: 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005;173:1701-1705.
31.
Sacco E, Prayer-Galetti T, Pinto F, Fracalanza S, Betto G, Pagano F, Artibani W: Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 2006;97:1234-1241.
32.
Glickman L, Godoy G, Lepor H: Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. J Urol 2009;181:731-735.
33.
Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF: Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436-445.
34.
Mundhenk J, Hennenlotter J, Alloussi S, Selbherr D, Martzog JC, Todenhofer T, Kruck S, Schwentner C, Stenzl A, Schilling D: Influence of body mass index, surgical approach and lymphadenectomy on the development of symptomatic lymphoceles after radical prostatectomy. Urol Int 2013;90:270-276.
35.
Park HJ, Ha YS, Park SY, Kim YT, Lee TY, Kim JH, Lee DH, Kim WJ, Kim IY: Incidence of upgrading and upstaging in patients with low-volume gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance. Urol Int 2013;90:301-305.
36.
Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK, Wilson TG, Zattoni F, Montorsi F: Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62:418-430.
37.
Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A, Menon M, Montorsi F, Patel VR, Stolzenburg JU, Van der Poel H, Wilson TG, Zattoni F, Mottrie A: Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405-417.
38.
Lumen N, Van Praet C, De Troyer B, Fonteyne V, Oosterlinck W, Decaestecker K, Mottrie A: Safe introduction of robot-assisted radical prostatectomy after a training program in a high-volume robotic centre. Urol Int 2013;91:145-152.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.